Products
Itolizumab Biosimilar Monoclonal Antibody (CD6) for Research
Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-284-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody |
| INN Name | Itolizumab |
| Target | TP120 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium |
| Conditions Approved | Plaque psoriasis |
| Conditions Active | Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis |
| Conditions Discontinued | Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis |
| Development Tech | na |
About target - CD6
1. Protein T-cell differentiation antigen CD6
2. Gene CD6
3. Organism Homo sapiens (Human)
Function
Cell adhesion molecule that mediates cell-cell contacts and regulates T-cell responses via its interaction with ALCAM/CD166 (PubMed:15048703, PubMed:15294938, PubMed:16352806, PubMed:16914752, PubMed:24945728, PubMed:24584089).
Contributes to signaling cascades triggered by activation of the TCR/CD3 complex (PubMed:24584089).
Functions as costimulatory molecule; promotes T-cell activation and proliferation (PubMed:15294938, PubMed:16352806, PubMed:16914752).
Contributes to the formation and maturation of the immunological synapse (PubMed:15294938, PubMed:16352806).
Functions as calcium-dependent pattern receptor that binds and aggregates both Gram-positive and Gram-negative bacteria. Binds both lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria (PubMed:17601777).
LPS binding leads to the activation of signaling cascades and down-stream MAP kinases (PubMed:17601777).
Mediates activation of the inflammatory response and the secretion of pro-inflammatory cytokines in response to LPS (PubMed:17601777).
